Shots: Bora acquires GSK’s facility located in Mississauga, Ontario (Canada) which produces ~50 products and employs ~400 skilled manufacturing staff. The transaction is expected to be completed in H2’20 As […]readmore
Tags : canada
Shots: The companies will collaboratively launch Bausch + Lomb Every Contact Counts recycling program in eyecare offices across Canada, allowing people to recycle their disposable contact lenses and blister pack […]readmore
Shots: JAMP to get exclusive commercialization right for Alvotech’s five biosimilar therapies, having the market value of ~2B annually in Canada The collaboration allows JAMP to expand its generic portfolio, […]readmore
Shots: JAMP Pharma to get exclusive commercialization rights for Alvotech’s five biosimilars in Canada. Alvotech will take care of full development and commercial supply of the biosimilars from their new […]readmore
Shots: Innovent to receive $45M as upfront, development & regulatory milestone and royalties on sales of the therapy in the licensed territories while Coherus plans to file BLA to the […]readmore
Shots: AstraZeneca to receive $35M upfront with future sales-contingent payments of up to $6M and it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition […]readmore
Shots: Health Canada approved Ofev (nintedanib) as the first and only treatment, indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease […]readmore
Shots: Onconova to receive $25.55M as clinical, regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada If approved, […]readmore
Shots: Novartis enters into a 3yrs. collaboration with MILA for transforming the discovery, development & commercialization of therapies by leveraging AI. The collaboration will lead to expansion of the pharmaceutical […]readmore
Shots: The safety & efficacy of Emgality (120mg after an initial loading dose of 240mg) is evaluated in three P-III studies EVOLVE-1, EVOlVE-2 and REGAIN study in comparison with PBO […]readmore